## Amendments to the Claims:

Please cancel Claims 4, 5, 15-21, 25, 26 and 36.

The Claim Listing below will replace all prior versions of the claims in the application:

## Claim Listing:

- $\overline{1}$ . (Original) A method for modulating the activity of a growth factor in a sample, which contains an activated  $\alpha 2$ -macroglobulin, comprising (a) contacting the sample with a fatty acid in an amount sufficient to inhibit the formation of a complex between the growth factor and the activated  $\alpha 2$ -macroglobulin, wherein (b) the fatty acid binds to the activated  $\alpha 2$ -macroglobulin.
- 2. (Original) The method of claim 1 wherein the fatty acid has a carbon chain length of at least 14.
- 3. (Original) The method of claim 2 wherein the fatty acid is a saturated fatty acid.
- 4-5. (Canceled)
- 6. (Original) The method of claim 2 wherein the fatty acid is an unsaturated fatty acid.
- 7. (Original) The method of claim 6 wherein the fatty acid is selected from the group consisting of arachidonic acid, oleic acid, γ-linolenic acid, linoleic acid, palmitoleic acid and linolenic acid.
- 8. (Original) The method of claim 7 wherein the fatty acid is arachidonic acid.
- 9. (Original) The method of claim 1 wherein the growth factor is selected from the group consisting of platelet-derived growth factor-AA, platelet-derived growth factor-BB, vascular endothelial cell growth factor, fibroblast growth factors, interleukins, growth hormone, insulin, insulin-like growth factor-1, insulin-like growth factor-2, nerve growth factor, neurotrophins and TGF-B.

- 10. (Original) The method of claim 9 wherein the growth factor is TGF-β.
- 11. (Original) The method of claim 10 wherein the TGF- $\beta$  is selected from the group consisting of TGF- $\beta$ 1, TGF- $\beta$ 2 and TGF- $\beta$ 3.
- 12. (Original) The method of claim 11 wherein the TGF-β is TGF-β1.
- 13. (Original) The method of claim 1 wherein the sample is a tissue or plasma.
- 14. (Original) The method of claim 13 wherein the tissue or plasma is in an animal.
- 15-21. (Canceled)
- 22. (Original) A method for modulating the activity of a growth factor in a sample, which contains an  $\alpha 2$ -macroglobulin-growth factor complex, comprising (a) contacting the sample with a fatty acid in an amount sufficient to promote the dissociation of the  $\alpha 2$ -macroglobulin-growth factor complex, wherein (b) the fatty acid binds to the  $\alpha 2$ -macroglobulin portion of the  $\alpha 2$ -macroglobulin-growth factor complex and (c) the growth factor dissociates from  $\alpha 2$ -macroglobulin.
- 23. (Original) The method of claim 22 wherein the fatty acid has a carbon chain length of at least 14
- 24. (Original) The method of claim 23 wherein the fatty acid is a saturated fatty acid.
- 25-26. (Canceled)
- 27. (Original) The method of claim 23 wherein the fatty acid is an unsaturated fatty acid.

- 28. (Original) The method of claim 27 wherein the fatty acid is selected from the group consisting of arachidonic acid, oleic acid, γ-linolenic acid, linoleic acid, palmitoleic acid and linolenic acid.
- 29. (Original) The method of claim 28 wherein the fatty acid is arachidonic acid.
- 30. (Original) The method of claim 1 wherein the growth factor is selected from the group consisting of platelet-derived growth factor-AA, platelet-derived growth factor-BB, vascular endothelial cell growth factor, fibroblast growth factors, interleukins, growth hormone, insulin, insulin-like growth factor-1, insulin-like growth factor-2, nerve growth factor, neurotrophins and TGF-8.
- 31. (Original) The method of claim 30 wherein the growth factor is TGF- β.
- 32. (Original) The method of claim 31 wherein the TGF-  $\beta$  is selected from the group consisting of TGF-  $\beta$ 1, TGF-  $\beta$ 2 and TGF-  $\beta$ 3.
- 33. (Original) The method of claim 32 wherein the TGF- β is TGF- β1.
- 34. (Original) The method of claim 22 wherein the sample is a tissue or plasma.
- 35. (Original) The method of claim 34 wherein the tissue or plasma is in an animal.
- 36. (Canceled)
- 37. (Original) A method of blocking the inhibitory effects of activated  $\alpha 2$ -macroglobulin on TGF- $\beta$  activity or reversing the inhibitory effects of activated  $\alpha 2$ -macroglobulin on TGF- $\beta$  activity comprising (a) contacting a sample, which comprises an activated  $\alpha 2$ -macroglobulin or an  $\alpha 2$ -macroglobulin-TGF- $\beta$  complex, with a fatty acid in an amount sufficient to (i) inhibit the formation of a complex between the TGF- $\beta$  and the activated

 $\alpha 2\text{-macroglobulin}$  or (ii) promote the dissociation of the  $\alpha 2\text{-macroglobulin-TGF-}\,\beta$  complex, wherein (b) the fatty acid binds to the activated  $\alpha 2\text{-macroglobulin}$  or the  $\alpha 2\text{-macroglobulin}$  portion of the  $\alpha 2\text{-macroglobulin-TGF-}\,\beta$  complex.